Some things will remain the same for Vertex five years from now, including its dominance in treating cystic fibrosis (CF). However, the company will likely achieve success in several new markets ...

Bruker Corporation today announced the launch of the VERTEX NEO Ultra, its most advanced and versatile benchtop vacuum Fourier-Transform Infrared (FT-IR) spectrometer. Building on the VERTEX NEO ...

This strengthens Google’s position against rivals such as Microsoft and AWS as enterprises seek faster, more reliable ways to deploy and manage AI agents. Google Cloud has updated its Vertex AI Agent ...

During Vertex’s third-quarter presentation, Chief Commercial Officer Duncan McKechnie cited several numbers that suggest the launch of its long-awaited, non-opioid pain reliever Journavx is trending ...

The potential approval of Vertex’s IgAN therapy povetacicept in 2026 comes amid launch headwinds for the company’s non-opioid pain medicine Journavx and gene therapy Casgevy. Vertex clocked 11% growth ...

Vertex delivered a split result this morning that left investors parsing mixed signals. The tax technology provider beat on EPS but missed revenue expectations. Shares were down nearly 10% by the ...

Good day, and welcome to the Vertex Inc. Third Quarter 2025 Earnings Conference Call. [Operator Instructions] Please note that this conference is being recorded. I would now like to turn the ...

Vertex, Inc. shares have plunged over 60% YTD, but valuation is now compelling after a post-earnings dip. VERX offers steady low-teens growth, expanding margins, and a sticky tax compliance software ...

Add Yahoo as a preferred source to see more of our stories on Google. This story was originally published on PharmaVoice. To receive daily news and insights, subscribe to our free daily PharmaVoice ...